Q/C Technologies, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price
Q/C Technologies, Inc. (QCLS) had Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price of $5.45 per share as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2026-08-12
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $5.45.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $5.64.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $23.42.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $863.26.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price as first filed |
|---|---|---|
| 2026-06-30 | $5.45 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $5.64 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $23.42 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $863.26 10-Q · filed 2025-11-19 | |
| 2025-06-30 | $9.64 10-Q · filed 2025-08-19 | |
| 2025-03-31 | $47.31 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $4595.20 10-K · filed 2026-04-15 | $45.97 10-K · filed 2025-04-11 |
| 2024-09-30 | $46.92 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $48.40 10-Q · filed 2024-08-19 | |
| 2024-03-31 | $42.34 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $42.34 10-K · filed 2025-04-11 | |
| 2023-09-30 | $1.42 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $1.80 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $2.64 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $78.64 10-K · filed 2024-04-01 | $2.64 10-K · filed 2023-03-31 |
| 2022-09-30 | $2.64 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $2.64 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $2.65 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $2.59 10-K · filed 2023-03-31 | |
| 2020-12-31 | $2.59 10-K · filed 2022-03-31 | |
| 2020-06-30 | $151.68 10-Q · filed 2020-08-14 | |
| 2020-03-31 | $151.68 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $151.68 10-K · filed 2021-03-01 | |
| 2019-09-30 | $6.32 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $7.46 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $14.80 10-Q · filed 2019-05-20 | |
| 2018-12-31 | $417.88 10-K · filed 2020-03-25 | $17.42 10-K · filed 2019-04-01 |
| 2018-09-30 | $17.44 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $2.53 10-Q · filed 2018-08-14 | |
| 2018-03-31 | $2.36 10-Q · filed 2018-07-13 | |
| 2017-12-31 | $20.49 10-K · filed 2019-04-01 | $2.36 10-K · filed 2018-04-03 |
| 2017-09-30 | $2.36 10-Q/A · filed 2018-07-13 | |
| 2017-06-30 | $2.36 10-Q/A · filed 2018-07-13 | |
| 2017-03-31 | $2.36 10-Q · filed 2017-05-15 | |
| 2016-12-31 | $2.36 10-Q/A · filed 2018-07-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |